Chimerix, Inc. (NASDAQ:CMRX) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Wednesday.
Separately, Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Wednesday, August 9th.
Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.05. Chimerix had a negative return on equity of 24.68% and a negative net margin of 1,514.27%. The company had revenue of $0.68 million during the quarter, compared to the consensus estimate of $1.28 million.
ILLEGAL ACTIVITY NOTICE: “ValuEngine Upgrades Chimerix, Inc. (CMRX) to “Sell”” was posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.com-unik.info/2017/10/13/valuengine-upgrades-chimerix-inc-cmrx-to-sell.html.
Institutional investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. bought a new stake in shares of Chimerix during the 1st quarter valued at about $776,000. Dimensional Fund Advisors LP grew its stake in shares of Chimerix by 114.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,043,336 shares of the biopharmaceutical company’s stock valued at $6,656,000 after purchasing an additional 557,927 shares during the period. Metropolitan Life Insurance Co. NY bought a new stake in shares of Chimerix during the 1st quarter valued at about $226,000. Geode Capital Management LLC grew its stake in shares of Chimerix by 11.7% during the 1st quarter. Geode Capital Management LLC now owns 341,238 shares of the biopharmaceutical company’s stock valued at $2,177,000 after purchasing an additional 35,752 shares during the period. Finally, Nationwide Fund Advisors grew its stake in shares of Chimerix by 5.9% during the 1st quarter. Nationwide Fund Advisors now owns 35,573 shares of the biopharmaceutical company’s stock valued at $227,000 after purchasing an additional 1,977 shares during the period. Institutional investors and hedge funds own 67.53% of the company’s stock.
Chimerix Company Profile
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
What are top analysts saying about Chimerix Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chimerix Inc. and related companies.